Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

151 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Measurable residual disease including AML leukemia stem cell flow evaluation of CPX-351 therapy by multi-parameter flow cytometry.
Plesa A, Roumier C, Gutrin J, Larcher MV, Balsat M, Cadassou O, Barraco F, Fossard G, Baudouin A, Labussière H, Tigaud I, Ducastelle S, Hayette S, Sujobert P, Heiblig M, Elhamri M, Thomas X. Plesa A, et al. Leuk Res. 2021 Dec;111:106673. doi: 10.1016/j.leukres.2021.106673. Epub 2021 Jul 26. Leuk Res. 2021. PMID: 34364023 No abstract available.
Treatment patterns and comparative effectiveness in elderly acute myeloid leukemia patients (age 70 years or older): the Lyon-university hospital experience.
Heiblig M, Le Jeune C, Elhamri M, Balsat M, Tigaud I, Plesa A, Barraco F, Labussière H, Ducastelle S, Nicolini F, Wattel E, Salles G, Thomas X. Heiblig M, et al. Among authors: plesa a. Leuk Lymphoma. 2017 Jan;58(1):110-117. doi: 10.1080/10428194.2016.1180688. Epub 2016 May 17. Leuk Lymphoma. 2017. PMID: 27184036
Molecular heterogeneity and measurable residual disease of rare NPM1 mutations in acute myeloid leukemia: a nationwide experience from the GBMHM study group.
Fournier E, Heiblig M, Lespinasse C, Flandrin-Gresta P, Geay A, Miguet L, Fenwarth L, Vallat L, Soubeyrand B, Marceau-Renaut A, Plesa A, Preudhomme C, Sujobert P, Hayette S, Duployez N, Huet S. Fournier E, et al. Among authors: plesa a. Leukemia. 2022 May;36(5):1390-1400. doi: 10.1038/s41375-022-01534-z. Epub 2022 Mar 7. Leukemia. 2022. PMID: 35256762 No abstract available.
The p16(INK4A)/pRb pathway and telomerase activity define a subgroup of Ph+ adult Acute Lymphoblastic Leukemia associated with inferior outcome.
Chien WW, Catallo R, Chebel A, Baranger L, Thomas X, Béné MC, Gerland LM, Schmidt A, Beldjord K, Klein N, Escoffre-Barbe M, Leguay T, Huguet F, Larosa F, Hayette S, Plesa A, Ifrah N, Dombret H, Salles G, Chassevent A, Ffrench M. Chien WW, et al. Among authors: plesa a. Leuk Res. 2015 Apr;39(4):453-61. doi: 10.1016/j.leukres.2015.01.008. Epub 2015 Jan 25. Leuk Res. 2015. PMID: 25675863
151 results